Fig. 3: EPO secretion from genetically modified FBs and TVC testing.
From: A therapeutic vascular conduit to support in vivo cell-secreted therapy
a EPO mRNA and EPO protein secretion from lentivirus-modified FBs programmed to constitutively secrete EPO. Wild-type (WT) and empty vector (EV) virus-infected cells were used as controls. b EPO mRNA and EPO protein secretion for FBs inserted with a doxycycline (dox)-inducible promoter for EPO secretion allowing for on/off signaling using dox. c Bioreactor set-up with the TVC with lumen flow through the center of the TVC. O2 in the lumen was maintained at 100 mmHg while the extravascular space was maintained at 40 mmHg. d Time course of EPO secretion from constitutive EPO-TVCs in the bioreactor setting and statically incubated at 40 mmHg O2. The majority of EPO was detected in the extravascular space of the bioreactor. For these experiments, n = 1.
